World Health Organization risk drinking levels as a treatment outcome measure in topiramate trials.

ABSTRACT:

Background

Although abstinence has traditionally been considered the only suitable outcome for alcohol treatment, reduced drinking is also associated with improved functioning and medical and psychiatric outcomes. The World Health Organization (WHO) risk drinking levels (RDLs) have been shown to be valid outcome measures in treatment trials for alcohol use disorder (AUD).

Methods

We conducted a secondary analysis of two 12-week, randomized controlled trials (RCTs), in which a total of 308 individuals with problematic alcohol use received topiramate or placebo treatment. We compared the utility of the WHO RDLs with other treatment outcomes, including self-reported measures of alcohol consumption, alcohol-related problems, and quality of life, and the biomarker gamma-glutamylt

SUBMITTER: Hartwell EE 

PROVIDER: S-EPMC9439581 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature